Glycyrrhizinは,HMGB1媒介の腎管状上皮細胞フェロプトーシスを抑制することによって,コントラスト誘発の急性腎損傷を軽減する
Fang-Yuan Tian1, Kun Liu1, Zhi-Yao Tang1
1Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Renal failure
|August 31, 2025
まとめ
グリシリジンは,腎臓細胞におけるフェロプトーシスを抑制することで,コントラスト誘発性急性腎臓損傷 (CI- AKI) を予防し,治療します. この化合物はHMGB1/AMPK/Beclin-1経路を標的にし,CI-AKIの潜在的な治療戦略を提供します.
科学分野:
- 腎臓科
- 薬理学について
- 分子生物学
背景:
- コントラスト誘発性急性腎損傷 (CI-AKI) は,治療の選択肢が限られている重大な臨床的課題です.
- グリシリジンは天然の化合物で,抗炎症性があることは知られていますが,CI-AKIにおけるその役割は未知のものです.
研究 の 目的:
- CI-AKIに対するグリシリジンの保護効果と治療効果を調査する.
- CI-AKIにおけるグリシリジン作用の基礎となる分子メカニズムを解明する.
主な方法:
- ラットとマウスのCI-AKIモデルを用いたin vivo試験
- 腎管状上皮細胞 (HK-2およびマウスの原始細胞) を用いたインビトロ研究
- 分子ドッキング,ネットワーク薬理学,遺伝子ノックアウト,遺伝子サイレンス技術が採用されました.
主要な成果:
- グリシリジン投与はCI- AKIモデルで腎機能障害と病理的損傷を緩和した.
- グリシリジン治療は,イオヘクソールにさらされた腎臓細胞の細胞活性を改善しました.
- GlycyrrhizinはHMGB1に直接結合し,HMGB1/AMPK/Beclin-1経路経由でフェロプトーシスを抑制する.
結論:
- グリシリジンは,CI- AKIに対する保護と治療の両方を示しています.
- このメカニズムは,HMGB1/AMPK/Beclin-1軸を通じた腎管状上皮細胞フェロプトーシスの抑制を伴う.
- グリシリジンはCI- AKI治療の有望な候補である.
関連する概念動画
01:29Acute Kidney Injury II: Pathophysiology
72
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
72
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
01:22Acute Kidney Injury I: Introduction
72
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
72
01:20Acute Kidney Injury V: Interprofessional Care
44
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
44
01:29Acute Kidney Injury III: Clinical Manifestations
90
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
90